Brain DiseasesDORKNCT07305948
Evaluation of a New MRI Technique to Reduce Breathing-Related Artifacts in Brain Imaging
An observational study of Brain Diseases, run by Region Stockholm at 1 site in Sweden.
Trial summary
This study aims to improve the quality of brain magnetic resonance imaging (MRI) scans by testing a new imaging method that reduces distortions caused by breathing. During respiration, small movements of the chest and diaphragm can lead to subtle changes in the magnetic field within the head. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain Diseases
- What is being tested?
- Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI)
- How many people
- 100 participants
- Where
- 1 siteSweden
- Study dates
- 2 Feb 2026to 16 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be selected from adult patients referred for routine clinical brain MRI examinations at Karolinska University Hospital in Stockholm, Sweden. These individuals represent a typical clinical population undergoing MRI for a wide range of neurological indications, including tumors, vascular disorders, inflammatory conditions, and other brain diseases. Only patients scheduled for standard-of-care brain MRI that includes a susceptibility-weighted sequence (SWI) will be approached for participation.
Who may be able to join
- Adult patients (18 years or older)
- Undergoing a routine clinical brain MRI at Karolinska University Hospital
- Able to understand the study information and provide written informed consent
- Sequence parameters and scan protocol compatible with the research acquisition (3D-EPI SWI)
Who cannot join
- Patients unable to give informed consent
- Standard contraindications to MRI (e.g., non-MRI safe implants, severe claustrophobia)
- Clinical conditions requiring urgent imaging where research consent is not feasible
- Significant motion or incomplete scans preventing creation of research images (rare)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Evaluation of a Free Induction Decay (FID) Navigator-Based Off-Resonance Correction Method (DORK) for Improving High-Resolution 3D Echo Planar (EPI) Susceptibility-Weighted (SWI) Brain MRI
This study aims to improve the quality of brain magnetic resonance imaging (MRI) scans by testing a new imaging method that reduces distortions caused by breathing. During respiration, small movements of the chest and diaphragm can lead to subtle changes in the magnetic field within the head. These changes can introduce artifacts in certain MRI techniques, particularly susceptibility-weighted imaging (SWI), which is used to visualize veins, small hemorrhages, and iron deposits.
The investigated method measures breathing-related magnetic field variations during MRI acquisition using two very short navigator signals, referred to as free induction decay (FID) navigators. These signals are used to perform dynamic off-resonance correction during image reconstruction, reducing image blurring and distortion. The method does not increase scan time and does not affect standard clinical imaging.
Read more
In this study, patients scheduled for routine clinical brain MRI are asked to provide informed consent for use of their raw MRI data for research purposes. For each participant, two sets of SWI images are generated from the same acquisition: one using standard reconstruction and one using the free induction decay navigator-based dynamic off-resonance correction method (FID-DORK). The objective is to assess whether the corrected images provide improved image quality and diagnostic reliability.
The study includes adult patients undergoing routine clinical MRI at Karolinska University Hospital. Image quality is evaluated using both visual assessment by neuroradiologists and quantitative measures of image variation. No additional imaging procedures, contrast agents, or scan time are required. All research data are pseudonymized prior to analysis.
The hypothesis is that the dual free induction decay navigator-based correction method (FID-DORK) improves the diagnostic quality of high-resolution three-dimensional echo-planar imaging susceptibility-weighted imaging brain MRI by reducing breathing-related artifacts.
- Conditions
- Brain Diseases
- Being tested
- Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI)
- Medical subject headings
- Brain Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI)Diagnostic test
This intervention consists of a modified magnetic resonance imaging (MRI) acquisition and reconstruction method used during routine clinical brain imaging. The method adds two very short free-induction-decay (FID) navigator signals to each repetition of a high-resolution 3D echo planar imaging (EPI) susceptibility-weighted imaging (SWI) sequence. These navigator signals measure breathing-related magnetic field changes, which are then used to perform dynamic off-resonance correction (DORK) during image reconstruction. The modified sequence does not change the clinical scan time or affect patient care. For each participant, both uncorrected and corrected SWI images are generated from the same raw data.
| Study group | Role | What they receive |
|---|---|---|
| Patients Undergoing Routine Clinical Brain MRI | Not described Receives: Diagnostic Test: Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Susceptibility-Weighted Imaging Image Quality With and Without Free Induction Decay Navigator-Based Dynamic Off-Resonance Correction (FID-DORK)
Image quality of susceptibility-weighted imaging scans reconstructed with and without free induction decay navigator-based dynamic off-resonance correction is compared. Image quality is assessed using visual ratings by neuroradiologists and quantitative measures of image variation. Differences in image quality between corrected and uncorrected reconstructions are evaluated.
Measured: Periprocedural (during the clinical brain MRI examination)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2025
- Study start2 Feb 2026
- Primary completion31 Jul 2026
- Study completion16 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain DiseasesStudies of the same condition, open and under way.
- More trials run by Region StockholmThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Stockholm
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07305948
- Sponsor's protocol ID
- K2025-9116
- Acronym
- DORK
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 7 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of a Free Induction Decay (FID) Navigator-Based Off-Resonance Correction Method (DORK) for Improving High-Resolution 3D Echo Planar (EPI) Susceptibility-Weighted (SWI) Brain MRI
- ClinicalTrials.gov ID
- NCT07305948
- Acronym / sponsor ID
- DORK / K2025-9116
- Conditions
- Brain Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Region StockholmOther government
- Study start
- 2 Feb 2026 (actual)
- Primary completion
- 31 Jul 2026 (actual)
- Study completion
- 16 Aug 2026 (actual)
- First posted
- 26 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to improve the quality of brain magnetic resonance imaging (MRI) scans by testing a new imaging method that reduces distortions caused by breathing. During respiration, small movements of the chest and diaphragm can lead to subtle changes in the magnetic field within the head. These changes can introduce artifacts in certain MRI techniques, particularly susceptibility-weighted imaging (SWI), which is used to visualize veins, small hemorrhages, and iron deposits.
The investigated method measures breathing-related magnetic field variations during MRI acquisition using two very short navigator signals, referred to as free induction decay (FID) navigators. These signals are used to perform dynamic off-resonance correction during image reconstruction, reducing image blurring and distortion. The method does not increase scan time and does not affect standard clinical imaging.
In this study, patients scheduled for routine clinical brain MRI are asked to provide informed consent for use of their raw MRI data for research purposes. For each participant, two sets of SWI images are generated from the same acquisition: one using standard reconstruction and one using the free induction decay navigator-based dynamic off-resonance correction method (FID-DORK). The objective is to assess whether the corrected images provide improved image quality and diagnostic reliability.
The study includes adult patients undergoing routine clinical MRI at Karolinska University Hospital. Image quality is evaluated using both visual assessment by neuroradiologists and quantitative measures of image variation. No additional imaging procedures, contrast agents, or scan time are required. All research data are pseudonymized prior to analysis.
The hypothesis is that the dual free induction decay navigator-based correction method (FID-DORK) improves the diagnostic quality of high-resolution three-dimensional echo-planar imaging susceptibility-weighted imaging brain MRI by reducing breathing-related artifacts.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients Undergoing Routine Clinical Brain MRI | – | Diagnostic Test: Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be selected from adult patients referred for routine clinical brain MRI examinations at Karolinska University Hospital in Stockholm, Sweden. These individuals represent a typical clinical population undergoing MRI for a wide range of neurological indications, including tumors, vascular disorders, inflammatory conditions, and other brain diseases. Only patients scheduled for standard-of-care brain MRI that includes a susceptibility-weighted sequence (SWI) will be approached for participation.
Key inclusion criteria (4 listed)
- Adult patients (18 years or older)
- Undergoing a routine clinical brain MRI at Karolinska University Hospital
- Able to understand the study information and provide written informed consent
- Sequence parameters and scan protocol compatible with the research acquisition (3D-EPI SWI)
Key exclusion criteria (4 listed)
- Patients unable to give informed consent
- Standard contraindications to MRI (e.g., non-MRI safe implants, severe claustrophobia)
- Clinical conditions requiring urgent imaging where research consent is not feasible
- Significant motion or incomplete scans preventing creation of research images (rare)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dual Free Induction Decay (FID) Navigator Off-Resonance Corrected (DORK) 3D Susceptibility Weighted (SWI) Echo Planar Imaging (EPI)This intervention consists of a modified magnetic resonance imaging (MRI) acquisition and reconstruction method used during routine clinical brain imaging. The method adds two very short free-induction-decay (FID) navigator signals to each repetition of a high-resolution 3D echo planar imaging (EPI) susceptibility-weighted imaging (SWI) sequence. These navigator signals measure breathing-related magnetic field changes, which are then used to perform dynamic off-resonance correction (DORK) during image reconstruction. The modified sequence does not change the clinical scan time or affect patient care. For each participant, both uncorrected and corrected SWI images are generated from the same raw data. | Diagnostic test | Patients Undergoing Routine Clinical Brain MRI |
Primary outcome
Susceptibility-Weighted Imaging Image Quality With and Without Free Induction Decay Navigator-Based Dynamic Off-Resonance Correction (FID-DORK)
Time frame: Periprocedural (during the clinical brain MRI examination)
Image quality of susceptibility-weighted imaging scans reconstructed with and without free induction decay navigator-based dynamic off-resonance correction is compared. Image quality is assessed using visual ratings by neuroradiologists and quantitative measures of image variation. Differences in image quality between corrected and uncorrected reconstructions are evaluated.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Brain Diseases
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Diseases, run by Region Stockholm at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Susceptibility-Weighted Imaging Image Quality With and Without Free Induction Decay Navigator-Based Dynamic Off-Resonance Correction (FID-DORK) (time frame: Periprocedural (during the clinical brain MRI examination)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.